ToxMinds are specialised in ensuring product safety and compliance.


We are passionate about toxicology and how emerging scientific developments can be utilised to support our customers in bringing safe, regulatory compliant and sustainable products to the marketplace.

Latest News

October 2020

Read our latest insight on the implementing regulation on the duties placed on registrants to update their registrations along with proposed deadlines under the EU REACH Regulation.



Our team of highly qualified (eco)toxicologists and regulatory specialists ensure that your products are safe to man and the environment and REACH compliant!


Obtaining biocidal product authorisation – ToxMinds supports companies marketing biocidal actives and products complying with the European Biocides Regulation.

Cosmetic & consumer products

Non-animal testing based safety assessment strategies for the cosmetics & consumer products industry.


Chemical risk assessment, PDE and MRL derivation services to companies from the pharmaceutical, veterinary medicines or medical device sectors.

Green biotechnology

Supporting the agribusiness and biotechnology sector with GM crop registration in accordance with the latest EFSA and EU legislative guidelines.


Mutagenicity assessment of drug impurities according to the ICH M7 (R1) guideline and the role of expert review

The evaluation of the genotoxicity potential of drug impurities has been the focus of regulatory recommendations issued by the United States Food and Drug Administration (FDA, 2008), European Medicines Agency (EMA, 2006 and 2010), and International Conference for Harmonization (ICH, 2014, 2015). In 2017, the ICH M7 issued a revised guideline providing a framework for the assessment and control of mutagenic impurities in pharmaceuticals.

Requirement of second species testing for evaluating developmental toxicity potential

Over the last decade, there has been ongoing debate on the regulatory requirement of a second-species testing requirement to identify developmental toxicity. A recent article by Braakhuis et al. (2019) has questioned the reproducibility of developmental toxicity results and the comparison approach using NOAELs. The current insight attempts to present the state-of-the-art information on the ongoing discussion.


Chemical and product safety

Ensuring chemical and product safety using emerging technology and state-of-the-art risk assessment practices.

Regulatory strategy and compliance

We help you to meet the regulatory demands and to stay compliant with EU Regulations.

Product stewardship

Ensuring publicly acceptable products – We help you to communicate the safety of your product to the public.

QSAR Modelling

Predicting toxicity, identifying suitable analogues for read-across and select lead candidates through combined use of public and commercial QSAR tools.

Endocrine disruption

Identifying and assessing the evidence for chemicals to cause endocrine disruption in humans and the environment.

New risk assessment methodologies

Identifying and applying new methodologies and risk assessment approaches to support chemical safety without animal testing.


ToxMinds supports a large, multinational cosmetic product manufacturer in prioritising new molecules for use in cosmetic applications from a consumer safety point of view.

Contact us